Clinical Trials Logo

Filter by:
NCT ID: NCT02207244 Completed - Psoriasis Clinical Trials

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

VOYAGE 2
Start date: November 3, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).

NCT ID: NCT02207231 Completed - Psoriasis Clinical Trials

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

VOYAGE 1
Start date: November 26, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.

NCT ID: NCT02205879 Completed - Alcoholism Clinical Trials

Pregabalin for Alcohol Dependence

Start date: January 2013
Phase: Phase 4
Study type: Interventional

The study hypothesis is: Pregabalin is superior to placebo in preventing relapse to drinking and reducing drinking severity

NCT ID: NCT02205359 Completed - Clinical trials for Heart Failure With Left Bundle Branch Block

AdaptResponse Clinical Trial

Start date: August 2014
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

NCT ID: NCT02203032 Completed - Psoriasis Clinical Trials

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

NAVIGATE
Start date: October 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab.

NCT ID: NCT02201290 Completed - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Start date: June 18, 2013
Phase: Phase 3
Study type: Interventional

This was an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450. This study allowed dosing of eltrombopag at an individualized dose for each subject based upon platelet count. The starting dose was based on the subject's dose at the end of the TRA115450 study. The maximum dose was 75 mg daily.

NCT ID: NCT02201251 Completed - Epilepsy Clinical Trials

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

Start date: October 6, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of topiramate monotherapy compared with levetiracetam another standard antiepileptic drug (AED), as monotherapy for new-onset or recent-onset epilepsy (seizure disorder) on pediatric growth and maturation, bone mineralization, and kidney stone formation in children aged 2 to 15 years.

NCT ID: NCT02200770 Completed - Clinical trials for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Start date: April 1, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.

NCT ID: NCT02200614 Completed - Clinical trials for Castration-Resistant

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

ARAMIS
Start date: September 12, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.

NCT ID: NCT02200029 Completed - Clinical trials for Intrahepatic Cholestasis Associated With Alcoholic Liver Disease

Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption

Start date: June 2014
Phase: Phase 3
Study type: Interventional

A research study of an approved drug called Heptral®, ademetionine, to treat adults with intrahepatic cholestasis (a condition where bile cannot flow from the liver to the duodenum) in pre-cirrhotic and cirrhotic states. Experience from clinical studies in subjects with liver disease has shown that ademetionine is effective.